Canopy Growth (TSE:WEED) Third Quarter 2025 Results
Key Financial Results
- Revenue: CA$74.8m (down 4.8% from 3Q 2024).
- Net loss: CA$121.9m (loss narrowed by 47% from 3Q 2024).
- CA$1.11 loss per share (improved from CA$2.78 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Canopy Growth Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 95%.
Looking ahead, revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Canopy Growth (1 makes us a bit uncomfortable!) that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Canopy Growth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.